LUPIN Q4
Hot stocks: Brokerage take on L&T Finance, Bajaj Finance, Gujarat Gas, Sun Pharma, and others
Brokerage firms such as UBS have maintained a buy rating on L&T Finance, while JP Morgan maintained an overweight rating on Bajaj Finance, Citi has initiated coverage on Indegene and maintained a sell rating on Gujarat Gas.
Lupin share price drops 5% post Q4 earnings
Lupin Share Price: Its revenue from operations in the same period jumped 12% YoY to Rs 4,961 crore as against Rs 4430 crore in the corresponding period of last year.
Hot Stocks: Brokerage view on Lupin and Gujarat Gas; Marico gets an upgrade
Investec raised Marico's rating from hold to buy, while Jefferies upheld a buy rating for Godrej Consumer. JPMorgan continued to rate Gujarat Gas as underweight and maintained a neutral stance on Lupin.
Lupin Q4 Results: Profit jumps 52% YoY to Rs 368 crore; revenue up 12%
Lupin reported a 52% YoY growth in net profit to Rs 368 crore for March 2024 quarter. Revenue increased by 12% to Rs 4,961 crore. The company declared a dividend of Rs 8 per share.
Q4 results this week: SBI, Tata Motors, L&T, Asian Paints, TVS Motor and PB Fintech
Various widely tracked companies like Tata Motors, SBI, Asian Paints, BPCL, Larsen & Toubro, Tata Power, Canara Bank, TVS Motor, Hero MotoCorp, Godrej Consumer Products, JSW Energy, Dr. Reddy's Laboratories, PB Fintech, and Bank of Baroda will be releasing their March quarter report cards this week. Here’s a list:
Q4 results preview: 29 companies likely to report doubling of profit
29 companies expected to double profits in Q4FY24 across various sectors like BFSI, Auto, Healthcare. Notable companies include Adani Ports, KEC International, Birla Corporation, JK Cements, United Breweries, Gland Pharma, Quess Corp Ltd, Signature Global, NMDC.
- Go To Page 1
Foram Parekh on what to bet on in pharma pack
Foram Parekh shares insights on CDMO companies' positive outlook post-Covid correction, potential impact of Biosecure Law, concerns about Laurus's earnings improvement, Sun Pharma's specialty sales focus, and recommendations for pharma sector growth with Lupin and Dr Reddy's.
Investing in bank, NBFC, automobile, healthcare, FMCG, oil and gas, metal or IT stocks? Know how India Inc performs in Q3
According to data compiled from a Motilal Oswal report, over 33% of the incremental year-on-year growth in Nifty 500 index earnings during the quarter was contributed by Indian Oil, HDFC Bank, Tata Motors, GAIL, and Adani Power. On comparing reported earnings with the expected earnings, most companies in sectors such as energy, construction materials and metals & mining reported earnings higher than Refinitiv estimates. Analysts are bullish on Indian equity markets, citing a stable macro environment with moderated inflation, steady crude prices, easing 10-year G-sec yield and stable currency.
LIC ditched these 19 smallcap stocks in Q3. End of the party or just a jittery exit?
Among smallcaps, Kaveri Seed was LIC ownership reducing by about half to 2.66% in Q3. In MOIL, LIC stake fell from 7.42% to 5.46% quarter-on-quarter, shows ACE Equity data.
Hot Stocks: Brokerage view on Page Industries, Zomato, Lupin and ITC
Macquarie maintained an underperform rating on Zomato with a target price of Rs 76. The company has seen steady margin improvements and strong Quick Commerce growth, it said.
Lupin Q3 Results: Net profit triples to Rs 619 crore on sales growth
The company reported a net profit of Rs 158 crore in the corresponding quarter of the previous year. Revenue from operations grew 20.2% YoY to Rs 5197 crore in Q3FY24.
Q3 results today: Nestle, Tata Consumer, Trent among 190 companies to announce earnings
On Tuesday, Nearly 160 companies will be announcing their December quarter earnings including the likes of Britannia Industries and FSN E-Commerce Ventures which operates Nykaa brand.
Pharma, not IT a proxy against weak dollar now; 4 stocks to play: Sanjiv Bhasin
Sanjiv Bhasin says: “There is enough room for ICICI Bank now to go to new highs. Do not play it for the next few days. This is one stock which should be in your portfolio for that 20% upside which will take it to that $100 billion club. This will be, by the way, the first fourth $100 billion entry.”
Hot Stocks: Brokerage view on Lupin, Godrej Consumer, Aarti Industries and Bata India
Morgan Stanley maintained an overweight rating on Aarti Industries with a target price of Rs 575. Agrochemicals make up one-third of Aarti's revenue.
Netflix movies, series: Most watched English, non-English films, shows of streaming giant
Netflix's most watched movies and series in the English and non-English categories have been unveiled.
Q2 results season kicks off this week. 32 companies may report over 100% profit growth
Domestic cyclicals like banks, auto and capital goods are likely to lead earnings growth while healthcare and technology may clock a moderate earnings growth. Motilal Oswal sees Nifty earnings growing by 21% YoY in Q2 while Kotak Equities has predicted 23% growth.
Hot Stocks: Brokerage view on Delhivery, Bank of Baroda, Lupin, SBI and M&M
Delhivery can sustain strong 18-20% revenue CAGR for a long period of time. Over the medium term, the brokerage firm sees adjusted EBIT margins of ~5-6%, with an asset turn of 3-4x.
What triggered Lupin’s growth spurt & can it be sustained?
"From Q2 onwards, we expected to get back to double digit growth and are very happy that it is happening in Q1 itself. The growth year on year was 10.2%. In fact, if we take out the Cidmus 50 effect from the base and adjust for price impact, the growth was actually 13.6% – ahead of market growth. And it is really the outcome of some of the efforts we have been putting in."
Lupin shares fall over 4%. Should you buy, sell or hold? Here's what brokerages say
Lupin witnessed a fall of over 4% to Rs 838.1 in intra-day trade on BSE after brokerages such as Jefferies, Kotak, and Bernstein maintained a reduce, underperform, and market-perform rating, respectively, on the stock. Jefferies found the gSpiriva approval positive but widely anticipated and indicated an expensive PE valuation. While Kotak believes gSpiriva's upside is priced in, it stays cautious given Lupin's weak execution record and subpar margin practice. Additionally, Bernstein stated that Lupin is trading higher than Sun Pharma.
Lupin shares hit 52-week high after launch of HIV drug Darunavir in US
Lupin's shares reached a 52-week high of INR 830.3 after it announced the launch of its Darunavir Tablets to market a generic equivalent of Janssen Products' Prezista Tablets. The estimated annual sales of Darunavir Tablets in the US is at around $308m (as of IQVIA MAT March 2023). Lupin also reported a surge in stock figures, having gained over 16% in a month and over 35% in a year. Furthermore, the stock's day RSI (14) is at 79.8 and MACD is at 24.7, indicating bullish signals.
Q4 results today: What to expect from Lupin, Apollo Tyres and Westlife Foodworld
Lupin, Apollo Tyres, Westlife, Raymond and Nazara are set to release their Q4 results on Tuesday. Lupin is expected to report a profit of Rs 233 crore, down from the last quarter but considerably better than the loss of Rs 518 crore reported last year. Apollo Tyres is expected to see its profit more than double to Rs 308 crore while Westlife Foodworld's profit is set to grow 37% to Rs 21 crore.
Q4 results this week: Tata Motors, L&T, Asian Paints, Vedanta, DLF and others
The March quarter earnings for IT companies have been disappointing, while the banking and finance sector has shown strong numbers. This week several significant companies such as Tata Motors, L&T, Asian Paints, DLF, Vedanta and Avenue Supermarts are releasing their March quarter report cards. On May 11, Eicher Motors, Aditya Birla Capital and ITI are set to release their reports. Meanwhile, Larsen & Toubro, Godrej Consumer Products and Dr Reddy's Laboratories will release theirs on May 10. Avenue Supermarts is set to release its report on May 13.
MSCI rejig, Q4 results among top 8 factors to drive Dalal Street this week
Bulls have had a good time since last month in Dalal Street due to continued buying by foreign investors and better corporate earnings. However, a series of events, economic data points, and earnings are due next week, resulting in some likely volatility in markets despite the positive trend. The coming week will include a review by the Bank of England and earnings releases by many Indian companies, along with various macro data points and an MSCI index review. Additionally, investors will watch the primary market as Mankind Pharma is expected to debut.
Q4 Results: 23 companies whose profit may more than double
Kotak Institutional Equities expects banks under its coverage to report a 45% year-on-year (YoY) earnings growth while its forecast for IT services' quarter-on-quarter (QoQ) revenue growth ranges from a decline of 2.1% to a growth of 2.3% across its coverage universe.
Analysts bearish on 'expensive' Lupin after Q3 disappoints, stock falls 9%
Of the 44 analysts, 18 of them have a 'sell' rating while 15 remain neutral. On aggregate, analysts slashed consensus price targets by 4.35% to ₹708.29, showed a Bloomberg poll of analysts.
Lupin Q3 Results: Profit slumps 72% to Rs 153 cr
Drug maker Lupin has reported 72 per cent decline in consolidated net profit at Rs 153 crore for the third quarter ended December 31, 2022. The company had reported a net profit of Rs 545 crore for October-December period last fiscal.
Lupin surges 4% on positive brokerage commentary post Q2
Macquarie maintained its 'outperform' rating on the stock with a 12-month target price of ₹790 per share as profitability missed estimates due to cost pressures after revenue came in line with expectations, it said.
Lupin shares jump over 8% after September quarter results
Manufacturing and other expenses were 30% of sales at Rs 1,226.8 crore compared to Rs 1,191.6 crore in Q1 FY2023. Investment in R&D for the quarter was Rs 337.6 crore (8.3% of sales), Lupin said in a BSE filing.
Lupin posts Rs 89 crore loss in Q1FY23 due to US price erosion, raw material inflation
“Our numbers are muted this quarter, but we expect a strong bounce back Q2 onwards. Our US sales took a significant dip as we took several strategic decisions to pave the way for building a sustainable and profitable business," said Nilesh Gupta, managing director of Lupin.
Load More
